{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:06:07Z","timestamp":1790215567344,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Swedish governmental funding for clinical research"},{"name":"The Swedish Breast Cancer Association"},{"name":"Region V\u00e4sternorrland (Visare Norr), Sweden"},{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The effectiveness of current follow-up guidelines after breast cancer treatment is uncertain. Tailored surveillance based on patient age and tumor characteristics may be more adequate. This study aimed to analyze the frequency of ipsilateral locoregional recurrences (LR) and second primary breast cancers (SP) detected outside of scheduled surveillance and to analyze risk factors associated with these events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with surgically treated early-stage breast cancer from the Malm\u00f6 Diet and Cancer Study (MDCS), 1991\u20132014 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091080), and the V\u00e4sternorrland region, 2009\u20132018 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091648), were included. Clinical and pathological information on the primary tumor and recurrences was retrieved from medical records. The mode of recurrence detection was defined as detection within (planned) or outside (symptomatic) of scheduled surveillance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up was 6.5 years. Overall, 461 patients experienced a recurrence. The most common initial event was distant metastasis (47%), followed by locoregional recurrence (LR) (22%) and second primary (SP) (18%). 56% of LR and 28% of SP were identified outside of scheduled surveillance. Logistic regression analysis revealed that younger age (under 50 years) (OR 2.57, 95% CI 1.04\u20136.88), lymph node-positive breast cancer (OR 2.10, 95% CI 1.03\u20134.39) and breast cancer of the HER2 positive subtype (OR 5.24, 95% CI 1.40\u201325.90) were correlated with higher odds of detecting a recurrence outside of planned surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most recurrent events were detected outside of scheduled surveillance, particularly for locoregional recurrences. Risk-based surveillance, which takes into account patient and tumor characteristics, might be more suitable for specific patient subsets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-024-07475-8","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T23:48:41Z","timestamp":1725925721000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance"],"prefix":"10.1007","volume":"209","author":[{"given":"Hanna","family":"Sartor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hemmingsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"L\u00e5ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-7265","authenticated-orcid":false,"given":"Charlotta","family":"Wadsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"7475_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010","journal-title":"Breast"},{"key":"7475_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T et al (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 72:409\u2013436. https:\/\/doi.org\/10.3322\/caac.21731","journal-title":"CA Cancer J Clin"},{"key":"7475_CR3","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v8\u2013v30. https:\/\/doi.org\/10.1093\/annonc\/mdv298","journal-title":"Ann Oncol"},{"key":"7475_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1200\/JCO.2012.45.9859","volume":"31","author":"JL Khatcheressian","year":"2013","unstructured":"Khatcheressian JL, Hurley P, Bantug E et al (2013) Breast Cancer Follow-Up and Management after Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 31:961\u2013965. https:\/\/doi.org\/10.1200\/JCO.2012.45.9859","journal-title":"J Clin Oncol"},{"key":"7475_CR5","unstructured":"RCC Nationellt v\u00e5rdprogram br\u00f6stcancer"},{"key":"7475_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012425.pub2","author":"BL H\u00f8eg","year":"2019","unstructured":"H\u00f8eg BL, Bidstrup PE, Karlsen RV et al (2019) Follow-up strategies following completion of primary cancer treatment in adult cancer survivors. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD012425.pub2. 2019:","journal-title":"Cochrane Database Syst Rev"},{"key":"7475_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10549-008-0023-4","volume":"114","author":"WL Lu","year":"2009","unstructured":"Lu WL, Jansen L, Post WJ et al (2009) Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 114:403\u2013412. https:\/\/doi.org\/10.1007\/s10549-008-0023-4","journal-title":"Breast Cancer Res Treat"},{"key":"7475_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/annonc\/mdp037","volume":"20","author":"N Houssami","year":"2009","unstructured":"Houssami N, Ciatto S, Martinelli F et al (2009) Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 20:1505\u20131510. https:\/\/doi.org\/10.1093\/annonc\/mdp037","journal-title":"Ann Oncol"},{"key":"7475_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10549-012-2297-9","volume":"136","author":"SME Geurts","year":"2012","unstructured":"Geurts SME, De Vegt F, Siesling S et al (2012) Pattern of follow-up care and early relapse detection in breast cancer patients. Breast Cancer Res Treat 136:859\u2013868. https:\/\/doi.org\/10.1007\/s10549-012-2297-9","journal-title":"Breast Cancer Res Treat"},{"key":"7475_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-020-05847-4","volume":"184","author":"L Saltb\u00e6k","year":"2020","unstructured":"Saltb\u00e6k L, Horsboel TA, Offersen BV et al (2020) Patterns in detection of recurrence among patients treated for breast cancer. Breast Cancer Res Treat 184:365\u2013373. https:\/\/doi.org\/10.1007\/s10549-020-05847-4","journal-title":"Breast Cancer Res Treat"},{"key":"7475_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.breast.2023.03.004","volume":"69","author":"A-A Beltran-Bless","year":"2023","unstructured":"Beltran-Bless A-A, Alshamsan B, Alzahrani MJ et al (2023) Regularly scheduled physical examinations and the detection of breast cancer recurrences. Breast 69:274\u2013280. https:\/\/doi.org\/10.1016\/j.breast.2023.03.004","journal-title":"Breast"},{"key":"7475_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2016.05.010","volume":"63","author":"KC Aalders","year":"2016","unstructured":"Aalders KC, Van Bommel ACM, Van Dalen T et al (2016) Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer 63:118\u2013126. https:\/\/doi.org\/10.1016\/j.ejca.2016.05.010","journal-title":"Eur J Cancer"},{"key":"7475_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN et al (2016) Annual Hazard Rates of recurrence for breast Cancer during 24 years of Follow-Up: results from the international breast Cancer Study Group trials I to V. J Clin Oncol 34:927\u2013935. https:\/\/doi.org\/10.1200\/JCO.2015.62.3504","journal-title":"J Clin Oncol"},{"key":"7475_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10549-016-4031-5","volume":"161","author":"LZ Braunstein","year":"2017","unstructured":"Braunstein LZ, Taghian AG, Niemierko A et al (2017) Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat 161:173\u2013179. https:\/\/doi.org\/10.1007\/s10549-016-4031-5","journal-title":"Breast Cancer Res Treat"},{"key":"7475_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-015-3490-4","volume":"152","author":"A Witteveen","year":"2015","unstructured":"Witteveen A, Vliegen IMH, Sonke GS et al (2015) Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat 152:627\u2013636. https:\/\/doi.org\/10.1007\/s10549-015-3490-4","journal-title":"Breast Cancer Res Treat"},{"key":"7475_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/SLA.0000000000005776","volume":"277","author":"JR Schumacher","year":"2023","unstructured":"Schumacher JR, Wiener AA, Greenberg CC et al (2023) Local\/Regional Recurrence Rates after breast-conserving therapy in patients enrolled in legacy trials of the Alliance for clinical trials in Oncology (AFT-01). Ann Surg 277:841\u2013845. https:\/\/doi.org\/10.1097\/SLA.0000000000005776","journal-title":"Ann Surg"},{"key":"7475_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamasurg.2023.2150","volume":"158","author":"J-H Cheun","year":"2023","unstructured":"Cheun J-H, Kim H-K, Moon H-G et al (2023) Locoregional recurrence patterns in patients with different molecular subtypes of breast Cancer. JAMA Surg 158:841. https:\/\/doi.org\/10.1001\/jamasurg.2023.2150","journal-title":"JAMA Surg"},{"key":"7475_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/00008469-200112000-00003","volume":"10","author":"J Manjer","year":"2001","unstructured":"Manjer J, Carlsson S, Elmst\u00e5hl S et al (2001) The Malm\u00f6 diet and cancer study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10:489\u2013499. https:\/\/doi.org\/10.1097\/00008469-200112000-00003","journal-title":"Eur J Cancer Prev"},{"key":"7475_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/14034948020300020401","volume":"30","author":"J Manjer","year":"2002","unstructured":"Manjer J, Elmstahl S, Janzon L, Berglund G (2002) Invitation to a population-based cohort study: differences between subjects recruited using various strategies. Scand J Public Health 30:103\u2013112. https:\/\/doi.org\/10.1177\/14034948020300020401","journal-title":"Scand J Public Health"},{"key":"7475_CR20","doi-asserted-by":"publisher","first-page":"20814","DOI":"10.1038\/s41598-020-77053-7","volume":"10","author":"L Sturesdotter","year":"2020","unstructured":"Sturesdotter L, Sandsveden M, Johnson K et al (2020) Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype. Sci Rep 10:20814. https:\/\/doi.org\/10.1038\/s41598-020-77053-7","journal-title":"Sci Rep"},{"key":"7475_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-6846-6","author":"L L\u00f6fgren","year":"2019","unstructured":"L\u00f6fgren L, Eloranta S, Krawiec K et al (2019) Validation of data quality in the Swedish National Register for Breast Cancer. BMC Public Health. https:\/\/doi.org\/10.1186\/s12889-019-6846-6","journal-title":"BMC Public Health"},{"key":"7475_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju288","author":"M Moossdorff","year":"2014","unstructured":"Moossdorff M, Van Roozendaal LM, Strobbe LJA et al (2014) Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. JNCI J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju288","journal-title":"JNCI J Natl Cancer Inst"},{"key":"7475_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<437::AID-CNCR23>3.0.CO;2-1","volume":"85","author":"AC Voogd","year":"1999","unstructured":"Voogd AC, Van Tienhoven G, Peterse HL et al (1999) Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Cancer 85:437\u2013446","journal-title":"Cancer"},{"key":"7475_CR24","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/sj.bjc.6603815","volume":"96","author":"DA Montgomery","year":"2007","unstructured":"Montgomery DA, Krupa K, Jack WJL et al (2007) Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 96:1802\u20131807. https:\/\/doi.org\/10.1038\/sj.bjc.6603815","journal-title":"Br J Cancer"},{"key":"7475_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.breast.2010.05.010","volume":"19","author":"N Houssami","year":"2010","unstructured":"Houssami N, Ciatto S (2010) Mammographic surveillance in women with a personal history of breast cancer: how accurate? How Effective? Breast 19:439\u2013445. https:\/\/doi.org\/10.1016\/j.breast.2010.05.010","journal-title":"Breast"},{"key":"7475_CR26","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/sj.bjc.6604065","volume":"97","author":"DA Montgomery","year":"2007","unstructured":"Montgomery DA, Krupa K, Cooke TG (2007) Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer 97:1632\u20131641. https:\/\/doi.org\/10.1038\/sj.bjc.6604065","journal-title":"Br J Cancer"},{"key":"7475_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ejca.2010.11.006","volume":"47","author":"W Lu","year":"2011","unstructured":"Lu W, De Bock GH, Schaapveld M et al (2011) The value of routine physical examination in the follow up of women with a history of early breast cancer. Eur J Cancer 47:676\u2013682. https:\/\/doi.org\/10.1016\/j.ejca.2010.11.006","journal-title":"Eur J Cancer"},{"key":"7475_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13244-018-0667-5","volume":"9","author":"J Swinnen","year":"2018","unstructured":"Swinnen J, Keupers M, Soens J et al (2018) Breast imaging surveillance after curative treatment for primary non-metastasised breast cancer in non-high-risk women: a systematic review. Insights Imaging 9:961\u2013970. https:\/\/doi.org\/10.1007\/s13244-018-0667-5","journal-title":"Insights Imaging"},{"key":"7475_CR29","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1001\/jamaoncol.2017.1256","volume":"3","author":"N Cho","year":"2017","unstructured":"Cho N, Han W, Han B-K et al (2017) Breast Cancer Screening with Mammography Plus Ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol 3:1495. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1256","journal-title":"JAMA Oncol"},{"key":"7475_CR30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1055-9965.EPI-12-1208-T","volume":"22","author":"N Houssami","year":"2013","unstructured":"Houssami N, Abraham LA, Kerlikowske K et al (2013) Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast Cancer participating in Mammography Screening. Cancer Epidemiol Biomarkers Prev 22:946\u2013961. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1208-T","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7475_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jso.23298","volume":"107","author":"D McNaul","year":"2013","unstructured":"McNaul D, Darke M, Garg M, Dale P (2013) An evaluation of post-lumpectomy recurrence rates: is follow\u2010up every 6 months for 2 years needed? J Surg Oncol 107:597\u2013601. https:\/\/doi.org\/10.1002\/jso.23298","journal-title":"J Surg Oncol"},{"key":"7475_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1148\/radiol.12111458","volume":"264","author":"VA Arasu","year":"2012","unstructured":"Arasu VA, Joe BN, Lvoff NM et al (2012) Benefit of Semiannual Ipsilateral Mammographic Surveillance following breast conservation therapy. Radiology 264:371\u2013377. https:\/\/doi.org\/10.1148\/radiol.12111458","journal-title":"Radiology"},{"key":"7475_CR33","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1245\/s10434-012-2578-x","volume":"19","author":"SR Gunia","year":"2012","unstructured":"Gunia SR, Merrigan TL, Poulton TB, Mamounas EP (2012) Evaluation of appropriate short-term mammographic surveillance in patients who undergo breast-conserving surgery (BCS). Ann Surg Oncol 19:3139\u20133143. https:\/\/doi.org\/10.1245\/s10434-012-2578-x","journal-title":"Ann Surg Oncol"},{"key":"7475_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41416-021-01417-7","volume":"125","author":"V Giannakeas","year":"2021","unstructured":"Giannakeas V, Lim DW, Narod SA (2021) The risk of contralateral breast cancer: a SEER-based analysis. Br J Cancer 125:601\u2013610. https:\/\/doi.org\/10.1038\/s41416-021-01417-7","journal-title":"Br J Cancer"},{"key":"7475_CR35","doi-asserted-by":"crossref","unstructured":"Dunn J (2023) Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography. In: SABCS. https:\/\/aacrjournals.org\/cancerres\/article\/84\/9_Supplement\/GS03-02\/743392\/Abstract-GS03-02-Mammographic-surveillance-in","DOI":"10.1158\/1538-7445.SABCS23-GS03-02"},{"key":"7475_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1054\/brst.2001.0404","volume":"11","author":"E Grunfeld","year":"2002","unstructured":"Grunfeld E, Noorani H, McGahan L et al (2002) Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast 11:228\u2013235. https:\/\/doi.org\/10.1054\/brst.2001.0404","journal-title":"Breast"},{"key":"7475_CR37","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/djac131","volume":"114","author":"JR Schumacher","year":"2022","unstructured":"Schumacher JR, Neuman HB, Yu M et al (2022) Surveillance Imaging vs Symptomatic Recurrence Detection and survival in stage II-III breast Cancer (AFT-01). JNCI J Natl Cancer Inst 114:1371\u20131379. https:\/\/doi.org\/10.1093\/jnci\/djac131","journal-title":"JNCI J Natl Cancer Inst"},{"key":"7475_CR38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10549-021-06335-z","volume":"189","author":"V V\u00f6lkel","year":"2021","unstructured":"V\u00f6lkel V, Hueting TA, Draeger T et al (2021) Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model. Breast Cancer Res Treat 189:817\u2013826. https:\/\/doi.org\/10.1007\/s10549-021-06335-z","journal-title":"Breast Cancer Res Treat"},{"key":"7475_CR39","doi-asserted-by":"crossref","unstructured":"Maaren MV, Hueting T, Uden DV et al (2024) The INFLUENCE 3.0 model: updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy","DOI":"10.21203\/rs.3.rs-4304136\/v1"},{"key":"7475_CR40","doi-asserted-by":"publisher","first-page":"103736","DOI":"10.1016\/j.breast.2024.103736","volume":"75","author":"K L\u00e5ng","year":"2024","unstructured":"L\u00e5ng K, Sturesdotter L, Bengtsson Y et al (2024) Mammographic features at primary breast cancer diagnosis in relation to recurrence-free survival. Breast 75:103736. https:\/\/doi.org\/10.1016\/j.breast.2024.103736","journal-title":"Breast"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07475-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07475-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07475-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:11:30Z","timestamp":1738321890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07475-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7475"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07475-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4801113\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the Declaration of Helsinki. The Malm\u00f6 Diet Cancer Study received approval from the Ethics Review Board in Lund, Sweden (Official Records Nos. 652\/2005, 166\/2007, and 2014\/830) as well as the Swedish Ethical Review Authority (2022-04473-02). The women from the MDCS cohort included in this study provided their informed consent at the baseline. For the V\u00e4sternorrland region, the Swedish Ethical Review Authority approved the data collection (2020\u201302165 and 2024-00428-02), waiving the need to secure informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}